(Q26777598)

1

0 references

author name string

Timothy G Albert

3

0 references

Rosaria Talarico

4

0 references

Marco Nardi

BioMed Research International

5

0 references

language of work or name

English

0 references

publication date

19 October 2015

9 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

19 June 2019

3 October 2019

21 October 2019

10 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

19 June 2019

3 October 2019

21 October 2019

2015

0 references

page(s)

120519

0 references

copyright license

Creative Commons Attribution 3.0 Unported

9 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

19 June 2019

3 October 2019

on focus list of Wikimedia project

21 October 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Ocular Involvement of Behçet's Syndrome: a Comprehensive Review

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Adalimumab (humira™) in ophthalmology: a review of the literature

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Ocular involvement in Adamantiades-Behçet's disease in Berlin, Germany

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Pattern of uveitis in Behçet's disease in a referral center in Tunisia, North Africa

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

EULAR recommendations for the management of Behçet disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Clinical features of chinese patients with Behçet's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Adalimumab for sight-threatening uveitis in Behçet's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Behçet's disease in Japan and in Great Britain: a comparative study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Treatment and visual prognosis in Behçet's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Short term cyclosporin A treatment of Behçet's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

A controlled trial of azathioprine in Behçet's syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

The eighth Frederick H. Verhoeff Lecture. presented by saiichi mishima, MD Behçet's disease in Japan: ophthalmologic aspects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Adalimumab: a new modality for Behçet's disease?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Azathioprine in Behcet's syndrome: effects on long-term prognosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Uveitis in Behçet disease: an analysis of 880 patients.

31 May 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Demographic and clinical features of uveitis in tertiary centers in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Childhood-onset uveitis in Behçet disease:a descriptive study of 36 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Switching biologic agents for uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2015%2F120519

Anakinra for resistant Behçet uveitis: why not?

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4628956

Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy

28 November 2018

1 reference

12 December 2020

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis

1 reference

12 December 2020

Behçet disease: visual prognosis and factors influencing the development of visual loss

1 reference

12 December 2020

Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

1 reference

12 December 2020

Comparison of patients with Behçet's disease in the 1980s and 1990s

1 reference

12 December 2020

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

1 reference

12 December 2020

Results of interferon-alfa therapy in patients with Behçet uveitis

1 reference

12 December 2020

Behçet's disease in Western Switzerland: epidemiology and analysis of ocular involvement

1 reference

12 December 2020

Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s

1 reference

12 December 2020

Behçet's disease: epidemiology and eye manifestations in German and Mediterranian patients

1 reference

12 December 2020

Prednisone and prednisolone in ocular disease

1 reference

12 December 2020

[Treatment of Behçet's disease with adalimumab]

1 reference

12 December 2020

Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN

1 reference

12 December 2020

The rate of visual loss in Behçet's disease

1 reference

12 December 2020